Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warns Against Power Morcellators For Uterine Fibroid Surgery

This article was originally published in The Gray Sheet

Executive Summary

FDA is discouraging use of laparoscopic power morcellation as a therapy for uterine fibroids due to risk of spreading cancer tissue. The agency has instructed manufacturers to ensure that device labeling accurately displays risks; it is planning an advisory panel meeting on the topic for the summer.

You may also be interested in...



Olympus Settles Power Morcellation Suit

The company was sued by a Georgia woman who said the surgical tool allowed uterine cancer to spread throughout her abdomen. Terms of the settlement were not disclosed.

Dr. Amy Reed, Anti-Power Morcellator Activist, Dead At 44

Anesthesiologist Amy Reed, who with her cardiologist husband Hooman Noorchasm turned her battle against uterine cancer into a crusade to abolish unsafe uses of power morcellators, died May 24 at her home in Yardley, Pa., at the age of 44.

Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans

Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel